Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Generate Biomedicines Inc (GENB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$12.57-11.23%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for GENB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS loss narrows from -$2.24 in FY26 to -$2.06 in FY27 | The company is not loss-making and aims to improve earnings from -$2.24 to -$2.06 per share next year. | Broken | EPS loss worsens or stays below -$2.24 in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
GENB is a clinical-stage healthcare company whose prospects depend on advancing its drug trials. Management has made progress on key programs, but recent earnings misses and declining cash reserves leave the long-term thesis in an insufficient-evidence state.
The valuation evidence labels expectations as justified, with a negative expectations gap, but does not explain the specific market assumptions. The snapshot gives no peer comparison, so whether GENB is cheap, fair, or expensive versus peers is unclear.
Near term, earnings-miss risk is elevated, and the company has missed in each of the two reported recent quarters. Over the multi-year view, trial advancement and higher research spending support the clinical effort, while cash fell from $516.6 million to $457.4 million; management says it can fund operations into the first half of 2028 but expects to need additional capital for longer-term operations.
The thesis depends on continued progress in GB-0895, GB-4362, and GB-5267, alongside enough funding to sustain their development. Near term, a weakening jobs trend could weigh on cyclical healthcare names, while results and guidance from sector bellwethers could either support or weaken the sector backdrop.
For the next 1 to 3 years, GENB has visible clinical activity and a supportive sector backdrop, but earnings risk, cash use, and future funding needs keep the long-term thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| A supporting condition in Generate Biomedicines Inc's published investment case. The stated target is sustain platform innovation and partnerships. |
| Intact |
| loss of key partnerships or platform setbacks |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to at least $25.9M in FY26 | A primary condition in Generate Biomedicines Inc's published investment case. The stated target is >= $25.9M. | Intact | revenue falls below $25M in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.06 → $-2.29 · observed estimates
$0.02B → $0.02B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.06 | $23,665,670 | 4 / 6 |
| 2026-07-25 | $-2.15 | $23,665,672 | 3 / 5 |
| 2026-07-26 | $-2.06 | $23,665,670 | 4 / 6 |
| 2026-07-27 | $-2.06 | $23,665,670 | 4 / 6 |
| 2026-07-28 | $-2.15 | $23,665,672 | 4 / 5 |
| 2026-07-29 | $-2.06 | $23,665,670 | 4 / 6 |
| 2026-07-30 | $-2.06 | $23,665,670 | 4 / 6 |
| 2026-07-31 | $-2.06 | $23,665,670 | 4 / 6 |
| 2026-08-01 | $-2.15 | $23,665,672 | 4 / 5 |
| 2026-08-02 | $-2.15 | $23,665,672 | 4 / 5 |
| 2026-08-03 | $-2.06 | $23,665,670 | 4 / 6 |
| 2026-08-04 | $-2.15 | $23,665,672 | 4 / 5 |
| 2026-08-05 | $-2.15 | $23,665,672 | 4 / 5 |
| 2026-08-06 | $-2.06 | $23,665,670 | 4 / 6 |
| 2026-08-07 | $-2.15 | $23,665,672 | 4 / 5 |
| 2026-08-08 | $-2.28 | $23,248,510 | 4 / 4 |
| 2026-08-09 | $-2.28 | $23,248,510 | 4 / 4 |
| 2026-08-10 | $-2.28 | $23,248,510 | 4 / 4 |
| 2026-08-12 | $-2.28 | $23,832,340 | 4 / 6 |
| 2026-08-13 | $-2.28 | $23,832,340 | 4 / 6 |
| 2026-08-14 | $-2.15 | $23,665,672 | 4 / 5 |
| 2026-08-15 | $-2.15 | $23,665,672 | 4 / 5 |
| 2026-08-16 | $-2.15 | $23,665,672 | 4 / 5 |
| 2026-08-17 | $-2.15 | $23,665,672 | 4 / 5 |
| 2026-08-18 | $-2.15 | $23,665,672 | 4 / 5 |
| 2026-08-19 | $-2.15 | $23,665,672 | 4 / 5 |
| 2026-08-20 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-08-21 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-08-22 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-08-23 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-08-24 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-08-25 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-08-26 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-08-27 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-08-28 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-08-29 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-08-30 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-08-31 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-09-01 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-09-02 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-09-03 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-09-04 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-09-05 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-09-06 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-09-07 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-09-08 | $-2.29 | $23,827,005 | 4 / 4 |
| 2026-09-09 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-10 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-11 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-12 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-13 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-14 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-15 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-16 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-17 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-18 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-19 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-20 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-21 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-22 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-23 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-24 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-25 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-26 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-27 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-28 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-29 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-09-30 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-01 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-02 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-03 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-04 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-05 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-06 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-07 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-08 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-09 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-10 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-11 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-12 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-13 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-14 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-15 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-16 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-17 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-18 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-19 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-20 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-21 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-22 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-23 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-24 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-25 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-26 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-27 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-28 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-29 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-30 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-10-31 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-11-01 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-11-02 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-11-03 | $-2.29 | $23,832,339 | 4 / 4 |
| 2026-11-04 | $-2.29 | $23,832,339 | 4 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.